Surmodics, Inc. to Post FY2025 Earnings of $0.13 Per Share, Zacks Research Forecasts (NASDAQ:SRDX)

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Analysts at Zacks Research increased their FY2025 EPS estimates for shares of Surmodics in a report issued on Wednesday, October 9th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.13 per share for the year, up from their previous estimate of $0.10. The consensus estimate for Surmodics' current full-year earnings is ($0.47) per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at $0.24 EPS, Q1 2026 earnings at $0.24 EPS, Q2 2026 earnings at $0.11 EPS and FY2026 earnings at $0.75 EPS.

SRDX has been the topic of several other reports. Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research note on Monday, August 5th. StockNews.com began coverage on shares of Surmodics in a report on Monday. They set a "hold" rating for the company. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $50.00.

Surmodics Stock Performance

Shares of Surmodics stock traded down $0.25 during trading on Monday, hitting $38.32. 73,955 shares of the stock were exchanged, compared to its average volume of 229,678. The stock has a market capitalization of $546.44 million, a price-to-earnings ratio of 40.53 and a beta of 1.20. The company has a fifty day moving average price of $39.42 and a 200-day moving average price of $37.33. Surmodics has a 1-year low of $25.17 and a 1-year high of $42.44. The company has a current ratio of 3.98, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.04. The company had revenue of $30.34 million for the quarter, compared to analyst estimates of $30.32 million. Surmodics had a negative net margin of 1.16% and a positive return on equity of 3.88%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Hardin Capital Partners LLC acquired a new position in shares of Surmodics during the 2nd quarter worth approximately $206,000. SG Americas Securities LLC grew its position in shares of Surmodics by 14.7% during the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company's stock worth $151,000 after purchasing an additional 660 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Surmodics during the 2nd quarter worth approximately $229,000. Lazard Asset Management LLC grew its position in shares of Surmodics by 13.4% during the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company's stock worth $166,000 after purchasing an additional 673 shares in the last quarter. Finally, Bailard Inc. acquired a new stake in shares of Surmodics during the 2nd quarter worth approximately $257,000. Institutional investors and hedge funds own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).